Adial Pharmaceuticals
ADIL
9 hedge funds and large institutions have $1.58M invested in Adial Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
61% more capital invested
Capital invested by funds: $980K → $1.58M (+$602K)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
18% less funds holding
Funds holding: 11 → 9 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$10.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$2K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$1K |
ADIL Hedge Fund Activity: Q4 2019 in Review
9 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q4 2019, worth a combined $1.58M — up 61% from $980K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ADIL and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Ladenburg Thalmann Financial Services, adding an estimated $10.5K. The largest seller was Victory Capital Management, exiting entirely with an estimated $2K sold.
- 9 institutional investors held Adial Pharmaceuticals (ADIL) as of Q4 2019, down from 11 in Q3 2019.
- Funds reported $1.58M of Adial Pharmaceuticals stock for Q4 2019, up 61% quarter-over-quarter.
- 0 funds opened new Adial Pharmaceuticals positions in Q4 2019 and 2 closed out, a net change of -2 holders.
- The largest Adial Pharmaceuticals buyer in Q4 2019 was Ladenburg Thalmann Financial Services, an estimated $10.5K added.
- The largest Adial Pharmaceuticals seller in Q4 2019 was Victory Capital Management, an estimated $2K sold.
Based on aggregated 13F filings for Q4 2019.